Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

The Lancet

Volumn 371, Issue 9617, 2008, Pages 1007-1016

  Nordlinger, Bernard ^a   Sorbye, Halfdan ^b   Glimelius, Bengt ^c,d   Poston, Graeme J ^e   Schlag, Peter M ^f   Rougier, Philippe ^a   Bechstein, Wolf O ^g   Primrose, John N ^h   Walpole, Euan T ⁱ   Finch Jones, Meg ^j   Jaeck, Daniel ^k   Mirza, Darius ^l   Parks, Rowan W ^m   Collette, Laurence ⁿ   Praet, Michel ⁿ   Bethe, Ullrich ⁿ   Van Cutsem, Eric ^o   Scheithauer, Werner ^p   Gruenberger, Thomas ^p  

^a HÔPITAL AMBROISE PARÉ   (France)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UPPSALA UNIVERSITY   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^f HUMBOLDT UNIVERSITY   (Germany)

^g UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^h SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY OF QUEENSLAND   (Australia)

^j BRISTOL ROYAL INFIRMARY   (United Kingdom)

^k HÔPITAL DE HAUTEPIERRE   (France)

^l UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^m ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

ⁿ EORTC DATA CENTER   (Belgium)

^o UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^p MEDICAL UNIVERSITY OF VIENNA   (Austria)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ABDOMINAL INFECTION; ADULT; AGED; ALLERGY; ARTICLE; ASCITES; BILE DUCT FISTULA; BLEEDING; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CARDIOPULMONARY INSUFFICIENCY; CARDIOVASCULAR DISEASE; CATHETER INFECTION; CLINICAL TRIAL; COLORECTAL CANCER; COLOSTOMY; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE COURSE; DRUG FATALITY; DYSESTHESIA; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HUMAN; INTERMETHOD COMPARISON; KIDNEY FAILURE; LEUKOPENIA; LIVER FAILURE; LIVER METASTASIS; LUNG DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PATIENT COMPLIANCE; PERIOPERATIVE PERIOD; PHARYNGITIS; PLEURA EFFUSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; WOUND INFECTION;

EID: 40749149728     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60455-9     Document Type: Article

References (30)

1. Fong Y., Fortner J., Sun R., Brennan M., and Blumgart L. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230 (1999) 309-318
2. Nordlinger B., Guiguet M., Vaillant J.-C., et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Cancer 77 (1996) 1254-1262
3. Giacchetti S., Itzhaki M., Gruia G., et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10 (1999) 663-669
4. Andre T., Boni C., Mounedji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 (2004) 2343-2351
5. Lorenz M., Muller H., Schramm H., et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg 228 (1998) 756-762
6. Kemeny N., Huang Y., Cohen A., et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 341 (1999) 2039-2048
7. Kemeny M., Adak S., Gray B., et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-an intergroup study. J Clin Oncol 20 (2002) 1499-1505
8. Mitry E., Fields A., Bleiberg H., et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials. ASCO Annual Meeting Proceedings. J Clin Oncol 24 (2006) 152s
9. Portier G., Elias D., Bouche O., et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 24 (2006) 4976-4982
10. National Cancer Institute. Common toxicity criteria version 2.0 (April 30, 1999). http://ctep.cancer.gov/forms/CTCv20_4-30-992.pdf (accessed July 30, 2007).
11. Freedman L., and White S. On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial. Biometrics 32 (1976) 691-694
12. de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 (2000) 2938-2947
13. Cunningham D., Allum W., Stenning S., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355 (2006) 11-20
14. Therasse P., Arbuck S., Eisenhauer E., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
15. Hwang I., Shih W., and DeCani J. Group sequential designs using a family of type I error probability spending functions. Stat Med 9 (1990) 1439-1445
16. Kaplan E., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
17. Kalbfleisch J., and Prentice R. Statistical analysis of failure time data (1980), Wiley, New York 163-178
18. Adam R., Pascal G., Azoulay D., Tanaka K., Castaing D., and Bismuth H. Liver resection for colorectal metastases: the third hepatectomy. Ann Surg 238 (2003) 871-883
19. Kokudo N., Hasegawa K., and Makuuchi M. Control arm for surgery alone is needed but difficult to obtain in randomized trials for adjuvant chemotherapy after liver resection for colorectal metastases. J Clin Oncol 25 (2007) 1299-1300
20. Charnsangavej C., Clary B., Fong Y., Grothey A., Pawlik T., and Choti M. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 13 (2006) 1261-1268
21. Adam R., Pascal G., Castaing D., et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?. Ann Surg 240 (2004) 1052-1061
22. Rubbia-Brandt L., Audard V., Sartoretti P., et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15 (2004) 460-466
23. Bilchik A., Poston G., Curley S., et al. Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol 23 (2005) 9073-9078
24. Vauthey J., Pawlik T., Ribero D., et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24 (2006) 2065-2072
25. Karoui M., Penna C., Amin-Hashem M., et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 243 (2006) 1-7
26. Janunger K., Hafstrom L., and Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg 168 (2002) 597-608
27. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
28. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
29. Hoff P., and Ellis L. Targeted therapy trials: approval strategies, target validation, or helping patients?. J Clin Oncol 1 (2007) 1639-1641
30. National Cancer Institute. EORTC protocol 40051 BOS: randomized phase II trial evaluating the feasibility and tolerance of the combination of FOLFOX with cetuximab and the combination of FOLFOX with cetuximab and bevacizumab as perioperative treatment in patients with resectable liver metastases from colorectal cancer. http:\www.cancer.gov\clinicaltrials\EORTC-40051 (accessed July 30, 2007).